Olema Oncology to Participate in 8th Annual Evercore Healthcare Conference

Rhea-AI Summary

Olema Oncology (Nasdaq: OLMA) will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Wednesday, December 3, 2025 at 12:55 p.m. ET. The company is a clinical-stage biopharmaceutical focused on targeted therapies for breast cancer and related indications.

Live webcasts and recordings will be available, as permitted by the event host, in the Events and Presentations section of Olema’s investor relations website at ir.olema.com.

News Market Reaction

+8.11%

24 alerts

+8.11% News Effect

-5.1% Trough in 59 min

+$109M Valuation Impact

$1.45B Market Cap

0.2x Rel. Volume

On the day this news was published, OLMA gained 8.11%, reflecting a notable positive market reaction. Argus tracked a trough of -5.1% from its starting point during tracking. Our momentum scanner triggered 24 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $109M to the company's valuation, bringing the market cap to $1.45B at that time.

Data tracked by StockTitan Argus on the day of publication.

SAN FRANCISCO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Wednesday, December 3, 2025 at 12:55 p.m. ET.

Live webcasts and recordings of these presentations will be available, as permitted by the event host, in the Events and Presentations section of Olema’s investor relations website at ir.olema.com.

About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD), currently in two Phase 3 clinical trials. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical study. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit www.olema.com

Media and Investor Relations Contact
Courtney O’Konek
Vice President, Corporate Communications
Olema Oncology
media@olema.com

FAQ

When will Olema Oncology (OLMA) present at the Evercore Healthcare Conference?

Olema will present on Wednesday, December 3, 2025 at 12:55 p.m. ET.

Where can I watch the Olema (OLMA) fireside chat webcast?

Live webcast and recording will be available in the Events and Presentations section of Olema’s investor relations website at ir.olema.com, as permitted by the host.

What topics will Olema (OLMA) likely cover at the December 3, 2025 presentation?

The company will present recent developments and its clinical-stage programs focused on targeted therapies for breast cancer.

How can investors access the Olema (OLMA) presentation slides or replay after the Evercore event?

Slides or replay, if permitted by the event host, will be posted to Olema’s investor relations Events and Presentations page at ir.olema.com.

Will Olema (OLMA) management be available for investor Q&A at the Evercore Healthcare Conference?

The announcement notes a fireside chat format; specific Q&A availability is subject to the event agenda and host rules.